Exarafenib (KIN-2787) is a highly selective, potent, next-generation, pan-RAF inhibitor with activity across BRAF and RAS mutant human tumor cell models. Exarafenib has anticancer activity by suppression of downstream MAPK pathway signaling. KIN-2787 in combination with binimetinib demonstrated significant combination benefit in NRAS mutant melanoma models.
| Molecular Weight | 521.58 |
| Formula | C26H34F3N5O3 |
| CAS Number | 2639957-39-2 |
| Solubility (25°C) | DMSO 90 mg/mL |
| Storage | 4°C, protect from light, dry, sealed |
| Species | Mouse | Rat | Rabbit | Guinea pig | Hamster | Dog |
| Weight (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
| Body Surface Area (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
| Km factor | 3 | 6 | 12 | 8 | 5 | 20 |
| Animal A (mg/kg) = Animal B (mg/kg) multiplied by | Animal B Km |
| Animal A Km |
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
[3] Claus Garbe, et al. Recent Results Cancer Res. Vemurafenib
[5] Claus Garbe, et al. Recent Results Cancer Res. Vemurafenib
| Related Raf Products |
|---|
| Cyclorasin 9A5
Cyclorasin 9A5 is an 11-residue cell-permeable cyclic peptide that orthosterically inhibits the Ras-Raf protein interaction with an IC50 of 120 nM. |
| R18
R18 is a peptide antagonists of 14-3-3, with a KD of 70-90 nM. |
| PROTAC RAF degrader 1
PROTAC RAF degrader 1 is a PROTAC RAF degrader. |
| B-Raf IN 15
B-Raf IN 15 is a BRAF inhibitor. |
| Raf inhibitor 3
Raf inhibitor 3 is a Raf inhibitor. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
